Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9

VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily treatment-experienced HIV-1 patients will be presented in a Late-Breaker Abstract poster session at ASM Microbe on Saturday, June 9, in Atlanta.  The trial results detail data from the one-week, single-dose, randomized, double-blind, placebo-controlled portion of the pivotal trial of PRO140 in combination with optimized background anti-retroviral therapy (ART). Session 226: Late The post Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 appeared first on Public Wire.
http://bit.ly/2JiROpY